UK

Globally, IPOs in the biotechnology industry have slowed in the first quarter; however, biotech venture capital (VC) in the UK has remained strong since 2015, accounting for 27%, or £178 million ($201.8 million), of the EU’s total biotech VC financing. In 2015, £489 million was raised in VC, a 51.4% increase. The 2015 trend of larger VC rounds is forecast to continue in 2016, with companies moving toward fewer but bigger rounds. The UK leads the EU in biotech R&D pipeline projects, with 585 projects currently in development and 51 of them in Phase 3 development. Momentum in the industry is expected to continue in 2016 due to the strong R&D pipeline, VC funding and high rate of regulatory approvals.

Source: UK BioIndustry Association

< | >